GILDGilead Sciences

Health care · Biotechnology · Nasdaq

Employees: 17,000
Headquarters: Foster City, CA
CEO: Daniel Patrick O'Day
Next results: around Feb 9, 2027

RevenueFY2016–25 $29.4B+2.4% FY2024: $28.8B 10-K FY2025 · XBRL Net incomeFY2016–25 $8.5B+1672.9% FY2024: $480.0M 10-K FY2025 · XBRL Free cash flowFY2016–25 $9.5B−8.2% FY2024: $10.3B 10-K FY2025 · XBRL Operating marginFY2016–25 34.0%+28.3 pts 58.0% in FY2016 10-K FY2025 · XBRL

What changed

10-K filed Feb 24, 2026 against Feb 28, 2025

Area	What changed	Source
Risk factors	13 new paragraphs, nothing like them in the previous 10-K	10-K Item 1A
Accounting checks	11 other checks clear	10-K · XBRL
Insiders	No open-market buys in the last 90 days	Form 4
Filings	2 in the last 30 days	EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

What's new, in their words

10-K filed Feb 24, 2026

Paragraphs in Risk Factors that were not in the 10-K filed 2025-02-28. Quoted as filed.

In addition, future cell therapy products may be subject to a Risk Evaluation and Mitigation Strategy (“REMS”), which is a drug safety program that the U.S. Food and Drug Administration (“FDA”) may require for certain drugs. For example, until June 2025, Yescarta and Tecartus were subject to a REMS requirement to manage the risks of…
10-K, Item 1A

All 13 new paragraphs →

Accounting checks

latest 10-K

11 of 11 clear 0 worth a look. Checks, not verdicts.

✓
Receivables +11.2% vs revenue +2.4% (+8.8 pts)
✓
Cash from operations $10.0B vs net income $8.5B (FY ending 2025-12-31)
✓
Inventory +3.7% vs revenue +2.4% (+1.3 pts)
✓
Same auditor in both 10-Ks: Ernst & Young LLP
✓
No statement of substantial doubt about going concern
✓
No 8-K item 4.02 in the last 2 years
✓
No NT 10-K or NT 10-Q in the last 2 years
✓
No longer listed: Valuation of in-process research and development intangible asset. Same as last year: Government and commercial rebates
✓
No sentence in the 10-K concludes that controls were not effective because of a material weakness
✓
No 8-K item 2.06 in the last 2 years
✓
No 8-K item 1.03 in the last 2 years

How each check works, with sources →

In the last 30 days

All filings →

Oct 30, 202610-Q Quarterly report (10-Q) period ended Sep 30, 2026
Oct 29, 20268-K Quarterly results 8-K item 2.02

Get an email when this changes: new risk paragraphs, accounting items, insider purchases, a new 10-K or 10-Q. RSS feed

Work on GILD in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/GILD/export.csv") into a cell.